3,267 results match your criteria: "CA J.L.; and Bnei Zion Medical Center[Affiliation]"

CT/MRI LI-RADS 2024 Update: Treatment Response Assessment.

Radiology

November 2024

From the Department of Radiology, University of Michigan Health System, 1500 E Medical Center Dr, Ann Arbor, MI 48109-5030 (A.A., M.M.L.); Department of Radiology, Memorial Sloan Kettering Medical Center, New York, NY (V.C., R.D., H.Y.); Department of Radiology, Northwestern Medical Center, Chicago, Ill (F.H.M., R.J.L.); Department of Radiology, Duke University Medical Center, Durham, NC (M.B.); Department of Radiology, University of California San Diego, San Diego, Calif (C.S., C.Y.K.); Department of Radiology, University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.R.K., A.S.B.); Department of Radiology, Mount Sinai Medical Center, New York, NY (E.K.); Department of Radiology, Mayo Clinic Rochester, Rochester, Minn (D.O.); Department of Radiology, Weill Cornell Medical Center, New York, NY (R.A.C.); and Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC (L.M.B.).

With the rising incidence of hepatocellular carcinoma, there has been increasing use of local-regional therapy (LRT) to downstage or bridge to transplant, for definitive treatment, and for palliation. The CT/MRI Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Assessment (TRA) algorithm provides guidance for step-by-step tumor assessment after LRT and standardized reporting. Current evidence suggests that the algorithm performs well in the assessment of tumor response to arterial embolic and loco-ablative therapies and fair when assessing response to radiation-based therapies, with limited data to validate the latter.

View Article and Find Full Text PDF

Association of Initial Side of Brain Atrophy With Clinical Features and Disease Progression in Patients With Frontotemporal Dementia.

Neurology

December 2024

From the Alzheimer's Disease and Other Cognitive Disorders Unit (S.B.-E., J.J.-P., A.P.M., M.B., A.L., R.S.-V.), Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Fundació Clínic per a la Recerca Biomèdica, Universitat de Barcelona, Spain; VIB Center for Molecular Neurology (M.V., R.R.); Department of Biomedical Sciences (M.V., R.R.), University of Antwerp, Belgium; Dementia Research Centre (A.B., L.L.R., P.H.F., E.F.-B., J.D.R.), Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, United Kingdom; Department of Neurology (J.C.V.S., L.C.J., H.S.), Erasmus Medical Centre, Rotterdam, Netherlands; Clinique Interdisciplinaire de Mémoire (R.L.), Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Division of Neurogeriatrics, Bioclinicum (C.G.), Department of Neurobiology, Care Sciences and Society; Center for Alzheimer Research, Karolinska Institutet; Unit for Hereditary Dementias (C.G.), Theme Inflammation and Aging, Karolinska University Hospital, Solna, Sweden; Department of Biomedical (D.G.), Surgical and Dental Sciences, University of Milan; Fondazione Ca' Granda (D.G.), IRCCS Ospedale Policlinico, Milan, Italy; Laboratory for Cognitive Neurology (R.V.), Department of Neurosciences, KU Leuven; Neurology Service (R.V.), University Hospitals Leuven; Leuven Brain Institute (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Fondazione IRCCS Istituto Neurologico Carlo Besta (P.T.), Milano, Italy; Neurology Service (I.S.), Faculty of Medicine, University Hospital of Coimbra (HUC), University of Coimbra; Center for Neuroscience and Cell Biology (I.S.), Faculty of Medicine, University of Coimbra, Portugal; Division of Psychology Communication and Human Neuroscience (A.G.), Wolfson Molecular Imaging Centre, University of Manchester, United Kingdom; Department of Nuclear Medicine (A.G.), Center for Translational Neuro- and Behavioral Sciences, University Medicine Essen; Department of Geriatric Medicine (A.G.), Klinikum Hochsauerland, Arnsberg; Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) (J.L.); Munich Cluster of Systems Neurology (SyNergy) (J.L.), Munich, Germany; Department of Neurofarba (S.S.), University of Florence; IRCCS Fondazione Don Carlo Gnocchi (S.S.), Florence, Italy; Department of Neurology (M.O.), University of Ulm, Germany; Univ Lille (F.P.), France; Department of Psychiatry (S.D.), McGill University Health Centre, McConnell Brain Imaging Centre (S.D.), Montreal Neurological Institute, McGill University, Montreal, Québec, Canada; Medical Sciences Division (C.B.), Nuffield Department of Clinical Neurosciences, University of Oxford, Department of Brain Sciences (C.B.), Imperial College London, United Kingdom; Sorbonne Université (I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225; Centre de référence des démences rares ou précoces (I.L.B.), IM2A, Département de Neurologie; Département de Neurologie (I.L.B.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London; Tanz Centre for Research in Neurodegenerative Diseases (M.C.T.), Ontario; Sunnybrook Health Sciences Centre (M.M.), Sunnybrook Research Institute, University of Toronto, Canada; Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust (J.B.R.), University of Cambridge, United Kingdom; Department of Neurodegenerative Diseases (M.S.), Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Germany; Cognitive Disorders Unit (F.M.), Department of Neurology, Donostia Universitary Hospital, San Sebastian, Spain; Neurology Unit (B.B.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; and Department of Neuroscience (R.R.), Mayo Clinic, Jacksonville, FL.

Background And Objectives: Pathogenic variants in the gene cause frontotemporal dementia (FTD-) with marked brain asymmetry. This study aims to assess whether the disease progression of FTD- depends on the initial side of the atrophy. We also investigated the potential use of brain asymmetry as a biomarker of the disease.

View Article and Find Full Text PDF
Article Synopsis
  • * Researchers developed a new subunit vaccine using a stabilized mumps fusion glycoprotein (Pre-F) and a chimeric immunogen, which showed strong immune responses in mice against various mumps genotypes.
  • * The study identified specific antibodies against the Pre-F and hemagglutinin neuraminidase (HN), which could neutralize the virus effectively, suggesting these new immunogens could enhance existing vaccine-induced immunity or serve as improved vaccine options.
View Article and Find Full Text PDF

Extrachromosomal DNA (ecDNA) presents a major challenge for cancer patients. ecDNA renders tumours treatment resistant by facilitating massive oncogene transcription and rapid genome evolution, contributing to poor patient survival. At present, there are no ecDNA-specific treatments.

View Article and Find Full Text PDF

The cation-independent mannose 6-phosphate receptor (CI-MPR) is clinically significant in the treatment of patients with lysosomal storage diseases because it functions in the biogenesis of lysosomes by transporting mannose 6-phosphate (M6P)-containing lysosomal enzymes to endosomal compartments. CI-MPR is multifunctional and modulates embryonic growth and fetal size by downregulating circulating levels of the peptide hormone insulin-like growth factor 2 (IGF2). The extracellular region of CI-MPR comprises 15 homologous domains with binding sites for M6P-containing ligands located in domains 3, 5, 9, and 15, whereas IGF2 interacts with residues in domain 11.

View Article and Find Full Text PDF

An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivo.

Cell Rep

November 2024

Department of Biochemistry & Biophysics, Texas A&M University, College Station, TX 77840, USA. Electronic address:

Safe, effective, and low-cost oral antiviral therapies are needed to treat those at high risk for developing severe COVID-19. To that end, we performed a high-throughput screen to identify non-peptidic, non-covalent inhibitors of the SARS-CoV-2 main protease (Mpro), an essential enzyme in viral replication. NZ-804 was developed from a screening hit through iterative rounds of structure-guided medicinal chemistry.

View Article and Find Full Text PDF

Growth Hormone Neuroprotective Effects After an Optic Nerve Crush in the Male Rat.

Invest Ophthalmol Vis Sci

November 2024

Departamento de Neurobiología Celular y Molecular, Instituto de Neurobiología, Campus Juriquilla, Universidad Nacional Autónoma de México, Querétaro, Qro., México.

Purpose: Growth hormone (GH) has neuroprotective effects that have not been evaluated in the mammalian visual system. This study tested the hypothesis that GH administration can promote retinal neuroprotection in an optic nerve crush (ONC) model in male rats.

Methods: The ON was compressed for 10 seconds, and bovine GH was injected concomitantly to injury for 14 days (0.

View Article and Find Full Text PDF

Care Quality and Outcomes of Ischemic Stroke in Patients With Premorbid Dementia: Get With The Guidelines-Stroke Registry.

Stroke

December 2024

Calgary Stroke Program, Departments of Clinical Neurosciences and Community Health Sciences, the Hotchkiss Brain Institute, and the O'Brien Institute for Public Health, Cumming School of Medicine, University of Calgary, Calgary, Canada (E.E.S.).

Background: Patients with premorbid dementia have been generally excluded from trials of stroke therapies, and their dementia diagnosis may affect the care received. There are few data on the quality of stroke care and outcomes in these patients.

Methods: We compared the quality of care and outcomes for acute ischemic stroke patients with versus without premorbid dementia using national data from the Get With The Guidelines-Stroke registry between July 1, 2020, and December 31, 2021.

View Article and Find Full Text PDF

Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.

Cancer Cell

November 2024

Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, USA; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address:

Article Synopsis
  • * Out of 31 patients, 55% showed a significant drop in tumor activity (major pathologic response), along with increased immune cell presence in the tumors.
  • * Findings indicate that this combination therapy not only activates various immune responses but is also linked to specific genetic markers in immune cells and changes in gut microbiota, suggesting potential pathways for enhancing treatment outcomes.
View Article and Find Full Text PDF

Combinatorial transcription factor binding encodes cis-regulatory wiring of mouse forebrain GABAergic neurogenesis.

Dev Cell

January 2025

Department of Neurobiology, Physiology and Behavior, and Department of Psychiatry and Behavioral Sciences, University of California, Davis, Davis, CA 95618, USA. Electronic address:

Transcription factors (TFs) bind combinatorially to cis-regulatory elements, orchestrating transcriptional programs. Although studies of chromatin state and chromosomal interactions have demonstrated dynamic neurodevelopmental cis-regulatory landscapes, parallel understanding of TF interactions lags. To elucidate combinatorial TF binding driving mouse basal ganglia development, we integrated chromatin immunoprecipitation sequencing (ChIP-seq) for twelve TFs, H3K4me3-associated enhancer-promoter interactions, chromatin and gene expression data, and functional enhancer assays.

View Article and Find Full Text PDF

Tumors are complex assemblies of cellular and acellular structures patterned on spatial scales from microns to centimeters. Study of these assemblies has advanced dramatically with the introduction of high-plex spatial profiling. Image-based profiling methods reveal the intensities and spatial distributions of 20-100 proteins at subcellular resolution in 10-10 cells per specimen.

View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on the lung's development during the first trimester of human pregnancy, emphasizing its importance for life on land.
  • It utilizes advanced imaging and analysis techniques to map the protein-level organization of lung cells over various stages of gestation, examining more than 2 million cells.
  • The findings offer a detailed resource on the types of cells in the developing lung as well as their growth and spatial patterns, serving as a foundation for future research on respiratory health.
View Article and Find Full Text PDF

Several therapeutic agents have been approved for treating multiple myeloma, a cancer of bone marrow-resident plasma cells. Predictive biomarkers for drug response could help guide clinical strategies to optimize outcomes. In this study, we present an integrated functional genomic analysis of tumor samples from patients multiple myeloma that were assessed for their ex vivo drug sensitivity to 37 drugs, clinical variables, cytogenetics, mutational profiles, and transcriptomes.

View Article and Find Full Text PDF

Objective: Totally endoscopic coronary artery bypass (TECAB) procedures pose significant challenges, motivating the development of Octocon, an automated endoscopic connector designed for coronary anastomoses in off-pump and endoscopic settings. This feasibility study aimed to assess Octocon's functionality and maneuverability in closed-chest conditions during robot-assisted TECAB simulations.

Methods: The Octocon deployment comprises a 3-step procedure.

View Article and Find Full Text PDF

Hematological malignancies are associated with an increased risk of complications during SARS-CoV-2 infections. Primary series or monovalent booster vaccines reduce disease severity, hospitalization, and death among multiple myeloma patients. We characterized virus-neutralizing and spike-binding antibody profiles following monovalent (WA1) or bivalent (WA1/BA.

View Article and Find Full Text PDF

Background: The Multicenter Evaluation of the Duration of Therapy for Thrombosis in Children multinational, randomized clinical trial revealed noninferiority of a 6-week vs 3-month duration of anticoagulation for the treatment of provoked venous thromboembolism (VTE) in patients <21 years old in regard to net clinical benefit at 1 year.

Objectives: To evaluate noninferiority at 2 years.

Methods: Patients whose repeat imaging 6 weeks after VTE diagnosis did not show complete veno-occlusion were randomized to discontinue anticoagulation vs receive a total 3-month course and followed for 2 years for the occurrence of symptomatic recurrent VTE (efficacy outcome) and clinically relevant bleeding (safety outcome).

View Article and Find Full Text PDF

Atrasentan in Patients with IgA Nephropathy.

N Engl J Med

October 2024

From the Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (H.J.L.H.); the National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney (M.J.); the Division of Nephrology, University of Utah Health, Salt Lake City (D.E.K.); Stanford University, Stanford, CA (R.A.L.); the University of British Columbia, Vancouver, Canada (A. Levin); Mount Elizabeth Novena Hospital, Singapore (A. Liew); Peking University First Hospital, Beijing (H.Z.); Chinook Therapeutics, Seattle (T.G.); Novartis, East Hanover, NJ (A. Lodha, Y.W.); Novartis, Basel, Switzerland (R.R.); and the University of Leicester, Leicester, United Kingdom (J.B.).

Background: Patients with IgA nephropathy and severe proteinuria have a high lifetime risk of kidney failure. The efficacy and safety of the selective endothelin type A receptor antagonist atrasentan in reducing proteinuria in patients with IgA nephropathy are incompletely understood.

Methods: We are conducting a phase 3, multinational, double-blind, randomized, controlled trial involving adults with biopsy-proven IgA nephropathy, a total urinary protein excretion of at least 1 g per day, and an estimated glomerular filtration rate of at least 30 ml per minute per 1.

View Article and Find Full Text PDF

Phenoconversion in Women and Men With Isolated REM Sleep Behavior Disorder: A Retrospective Cohort Study.

Neurology

November 2024

From the Mayo Center for Sleep Medicine (C.A.A., S.J.M., G.M.T., L.L.-V., J.C.F., T.R.G., E.P.S., J.T.J., M.R.K., T.F., E.J.O., D.J.S., T.J.M., M.J., M.L., J.L.M., M.T.-P., D.Z.C., M.H.S., E.K.S.L.), Department of Neurology; Mayo Center for Sleep Medicine (S.J.M., G.M.T., L.L.-V., J.C.F., T.R.G., E.P.S., J.T.J., M.R.K., T.F., D.J.S., T.J.M., M.J., M.L., J.L.M., M.T.-P., D.Z.C., M.H.S., E.K.S.L.),; Department of Neurology (F.A., H.B., J.G.-R., R.S., W.S., B.F.B.); Department of Radiology (K.K.); Department of Cardiovascular Medicine (N.C., V.K.S.); Department of Medicine (J.L.K.); and Mayo Center for Sleep Medicine (C.A.M.), Department of Pediatrics, Mayo Clinic.

Article Synopsis
  • - The study investigates isolated REM sleep behavior disorder (iRBD) and its links to neurodegenerative diseases, focusing on gender differences and younger adults, which are less explored compared to older males.
  • - Researchers followed 372 participants (186 women and 186 men with iRBD), finding that women were diagnosed at a younger age than men and that over 12% converted to a neurodegenerative disorder within roughly 6 years.
  • - Key findings indicate that older age at diagnosis is a significant factor for phenoconversion risk, with lower risk observed in those using antidepressants or having chronic pain, while higher risk was noted in individuals with vascular issues.
View Article and Find Full Text PDF

Adult emergency resuscitative thoracotomy: A Western Trauma Association clinical decisions algorithm.

J Trauma Acute Care Surg

October 2024

From the Department of Surgery (R.T.), University of California, San Francisco, San Francisco, California; Comparative Effectiveness and Clinical Outcomes Research Center (R.C.), Riverside University Health Systems Medical Center, Moreno Valley; Loma Linda University School of Medicine (R.C.), Loma Linda, California; Scripps Memorial Hospital La Jolla (W.L.B.), La Jolla, California; University of Colorado (C.C.B.), Aurora, Colorado; University of Florida College of Medicine (C.A.C.), Gainesville, Florida; University of Maryland School of Medicine (C.F.), Baltimore, Maryland; University of Kansas Medical Center (J.L.H.), Kansas City, Kansas; University of Arizona College of Medicine-Phoenix (N.K.), Phoenix, Arizona; Methodist Dallas Medical Center (M.L.), Dallas, Texas; Division of Acute Care Surgery, Department of Surgery (M.J.M., M.S.), Los Angeles General Medical Center, Los Angeles, California; Division of Vascular Surgery and Endovascular Therapy (G.A.M.), Keck Medical Center of USC, Los Angeles, California; Division of Acute Care Surgery, Department of Surgery (L.J.M.), The University of Texas McGovern Medical School - Houston Red Duke Trauma Institute, Memorial Hermann Hospital, Houston, Texas; Medical University of South Carolina (A.R.P.), North Charleston, South Carolina; Yale School of Medicine (K.M.S.), New Haven, Connecticut; St. Joseph's Hospital and Medical Center (J.A.W.), Phoenix, Arizona; and Program in Trauma (D.M.S.), University of Maryland School of Medicine, Baltimore, Maryland.

View Article and Find Full Text PDF

Background/objectives: Mucin-1 (MUC1) is a transmembrane glycoprotein that is overexpressed and hypoglycosylated in premalignant and malignant epithelial cells compared to normal cells, creating a target antigen for humoral and cellular immunity. Healthy individuals with a history of advanced colonic adenomas and at high risk for colon cancer were enrolled in a clinical trial to evaluate the feasibility of using a MUC1 peptide vaccine to prevent colon cancer. Anti-MUC1 antibodies elicited by this vaccine were cloned using peripheral blood B cells and sera collected two weeks after a one-year booster.

View Article and Find Full Text PDF

Multiomic profiling of single cells by sequencing is a powerful technique for investigating cellular diversity. Existing droplet-based microfluidic methods produce many cell-free droplets, underutilizing bead barcodes and reagents. Combinatorial indexing on microplates is more efficient for barcoding but labor-intensive.

View Article and Find Full Text PDF

Objective: To compare the risk of hospitalization for infection among patients who achieve intensive versus relaxed glycemic control.

Research Design And Methods: This retrospective cohort study included adults age ≥65 years with type 2 diabetes from an integrated health care delivery system. Negative binomial models were used to estimate incidence rates and relative risk (RR) of hospitalization for infections (respiratory; genitourinary; skin, soft tissue, and bone; and sepsis), comparing two levels of relaxed (hemoglobin A1c [HbA1c] 7% to <8% and 8% to <9%) with intensive (HbA1c 6% to <7%) glycemic control from 1 January 2019 to 1 March 2020.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the relationship between proteomic features and outcomes related to right ventricular (RV) health in patients with pulmonary arterial hypertension (PAH), focusing on mortality, RV dilation, and NT-proBNP levels.
  • - A cohort of 117 PAH participants underwent proteomic profiling, revealing significant differences in protein abundance between survivors and nonsurvivors, as well as between patients with dilated and nondilated RVs, with a notable emphasis on extracellular matrix (ECM) proteins.
  • - The findings indicate that specific plasma proteomic profiles correlate with worse clinical outcomes in PAH, suggesting that ECM-related pathways may play a critical role in RV susceptibility to failure, and these results were validated in additional PAH
View Article and Find Full Text PDF

Designing a clinical trial to evaluate the efficacy of an intervention is often complicated by uncertainty over aspects of the study population, potential treatment effects, most relevant outcomes, dropouts, and other factors. However, once participants begin to be enrolled and partial trial data become available, this level of uncertainty is reduced. Adaptive clinical trials are designed to take advantage of the accumulating data during the conduct of a trial to make changes according to prespecified decision rules to increase the likelihood of success or statistical efficiency.

View Article and Find Full Text PDF